Summary
In vitro metabolism of perospirone was examined with rat, monkey and human liver S9, human liver microsomes and yeast microsomes expressing human P450, using14C labeled perospirone. With rat liver S9, the major metabolites were MX9 and ID-11614, produced by cleavage at the butylene chain. However, some butylene non-cleavage and hydration of the cyclohexane ring were found, although limited in extent. Unknown metabolites accounted for about 10% of the total. After incubation for 10 minutes with monkey liver S9, the major metabolites were ID-15036 and MX11, hydrated in the cyclohexane ring. After incubation for 60 minutes, ID-15001, i.e. the butylene chain cleavage type increased. Unknown metabolites accounted for about 20%. After incubation for 10 minutes with human liver S9, the major metabolite was ID-15036, hydrated in the cyclohexane ring. In addition, MX11 and many unknown metabolites were evident. After incubation for 60 minutes, the butylene chain cleavage type and unknown metabolites increased. Individual differences were found in the metabolic reaction rate. With human liver microsomes, MX11, ID-15001 and unknown metabolites were again the major metabolites. With yeast microsomes expressing human P450 subtypes, CYP1A1, 2C8, 2D6, 3A4 were responsible for the metabolism in particular, and CYP3A4 contributes greatly. Therefore it is unlikely that genetic polymorphism will arise a present a problem with regard to the clinical drug.
The results demonstrated that the main metabolic pathway in human liver S9 and liver microsomes involve oxidation at cyclohexane, oxidative cleavage of the butylene side chain and S-oxidation. The same was the case in rat and monkey S9, but species differences were found in the proportions of the metabolites produced.
Similar content being viewed by others
References
Hirose A., Kato T., Ohno Y., Shimizu H., Tanaka H., Nakamura M., Katsube J. (1990): Pharmacological Actions of SM-9018, a New Neuroleptic Drug with Both Potent 5-Hydroxytryptamine2 and Dopamine2 Antagonistic Actions. Japan. J. Pharmacol., 53, 321–329.
Fujimoto K., Mizuno Y., Kanamaru H., Nakatsuka I. (1997): Identification of metabolites of perospirone. Clinical Report, 31(2), 581–657.
Mizuno Y., Kanamaru H., Nakatsuka I. (1997): Metabolic Profile in Serum after Single Oral Administration of14C-SM-9018 to Rats. Clinical Report, 31(2), 689–705.
Mizuno Y., Kanamaru H., Nakatsuka I. (1997): Disposition of SM-9018 after Single Oral Administration to Rat and Protein Binding to Serum of Human and Animals. Clinical Report, 31(2), 543–568.
Mizuno Y., Kanamaru H., Nakatsuka I., Miyoshi K., Hanawa S., Hayashi K., Esumi Y. (1997): Disposition of [carbonyl-14C]SM-9018 in Cynomolgus monkeys. Clinical Report, 31(2), 799–809.
Mizuno Y., Kanamaru H., Nakatsuka I., Kitajima S., Mitsuoka C., Kodama R. (1997): Disposition of [isothiazolyl-14C]SM-9018 in Cynomolgus monkeys. Clinical Report, 31(2), 811–819.
Chiba H. (1994): The genetic polymorphism of human cytochrome P450 and the individual difference of drug interactions — relationship to adverse drug action and development of medicine — Pharmacia, 30, 154–159.
Inanaga K., Irie S., Urae A., Urae T. (1997): Phase I Study of Perospirone HCl(SM-9018). Clinical Report, 31(2), 2113–2157.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mizuno, Y., Tani, N., Komuro, S. et al. In vitro metabolism of perospirone in rat, monkey and human liver microsomes. Eur. J. Drug Metab. Pharmacokinet. 28, 59–65 (2003). https://doi.org/10.1007/BF03190868
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190868